222 related articles for article (PubMed ID: 31040252)
21. Phase II trial of S-1 plus cisplatin combined with bevacizumab for advanced non-squamous non-small cell lung cancer (TCOG LC-1202).
Miyanaga A; Kubota K; Hosomi Y; Okuma Y; Minato K; Fujimoto S; Okamoto H; Satouchi M; Isobe H; Aono H; Takiguchi Y; Gemma A;
Jpn J Clin Oncol; 2019 Aug; 49(8):749-754. PubMed ID: 31070750
[TBL] [Abstract][Full Text] [Related]
22. Phase II Study of Modified Carboplatin Plus Weekly Nab-Paclitaxel in Elderly Patients with Non-Small Cell Lung Cancer: North Japan Lung Cancer Study Group Trial 1301.
Miyauchi E; Inoue A; Usui K; Sugawara S; Maemondo M; Saito H; Fujita Y; Kato T; Suzuki T; Harada T; Watanabe H; Nakagawa T; Ichinose M
Oncologist; 2017 Jun; 22(6):640-e59. PubMed ID: 28526722
[TBL] [Abstract][Full Text] [Related]
23. An Exploratory Randomized Phase II Trial Comparing CDDP Plus S-1 With Bevacizumab and CDDP Plus Pemetrexed With Bevacizumab Against Patients With Advanced Non-squamous Non-small Cell Lung Cancer.
Kaira K; Imai H; Souma R; Sakurai R; Miura Y; Sunaga N; Kasahara N; Tsukagoshi Y; Koga Y; Kitahara S; Kotake M; Minato K; Naruse I; Fukushima Y; Hisada T; Ishizuka T
Anticancer Res; 2019 May; 39(5):2483-2491. PubMed ID: 31092443
[TBL] [Abstract][Full Text] [Related]
24. A randomized phase II study of bevacizumab in combination with docetaxel or S-1 in patients with non-squamous non-small-cell lung cancer previously treated with platinum based chemotherapy (HANSHIN Oncology Group 0110).
Nishino K; Imamura F; Kumagai T; Katakami N; Hata A; Okuda C; Urata Y; Hattori Y; Tachihara M; Yokota S; Nishimura T; Kaneda T; Satouchi M; Morita S; Negoro S
Lung Cancer; 2015 Aug; 89(2):146-53. PubMed ID: 26093793
[TBL] [Abstract][Full Text] [Related]
25. Phase I study of S-1 plus paclitaxel combination therapy as a first-line treatment in elderly patients with advanced non-small cell lung cancer.
Chihara Y; Date K; Takemura Y; Tamiya N; Kohno Y; Imabayashi T; Kaneko Y; Yamada T; Ueda M; Arimoto T; Uchino J; Iwasaki Y; Takayama K
Invest New Drugs; 2019 Apr; 37(2):291-296. PubMed ID: 30121935
[TBL] [Abstract][Full Text] [Related]
26. Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC.
Sugawara S; Nakagawa K; Yamamoto N; Nokihara H; Ohe Y; Nishio M; Takahashi T; Goto K; Maemondo M; Ichinose Y; Seto T; Sakai H; Gemma A; Imamura F; Shingyoji M; Saka H; Inoue A; Takeda K; Okamoto I; Kiura K; Morita S; Tamura T
Int J Clin Oncol; 2019 May; 24(5):485-493. PubMed ID: 30830659
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of combination therapy with S-1 and irinotecan for advanced non-small cell lung cancer: west Japan thoracic oncology group 3505.
Okamoto I; Nishimura T; Miyazaki M; Yoshioka H; Kubo A; Takeda K; Ebi N; Sugawara S; Katakami N; Fukuoka M; Nakagawa K
Clin Cancer Res; 2008 Aug; 14(16):5250-4. PubMed ID: 18698044
[TBL] [Abstract][Full Text] [Related]
28. A phase I study of bi-weekly combination therapy with S-1 and docetaxel for advanced or recurrent gastric cancer.
Rino Y; Takanashi Y; Yukawa N; Saeki H; Wada H; Kanari M; Yamada R; Satoh T; Yamamoto N; Imada T
Anticancer Res; 2006; 26(2B):1455-62. PubMed ID: 16619558
[TBL] [Abstract][Full Text] [Related]
29. A phase I study of S-1 and irinotecan combination therapy in previously treated advanced non-small cell lung cancer patients.
Yoda S; Soejima K; Yasuda H; Naoki K; Kawada I; Watanabe H; Nakachi I; Satomi R; Nakayama S; Ikemura S; Terai H; Sato T; Morosawa M; Asano K
Cancer Chemother Pharmacol; 2011 Mar; 67(3):717-22. PubMed ID: 21152917
[TBL] [Abstract][Full Text] [Related]
30. Phase 1 Dose-Escalation Study of Triweekly Nab-Paclitaxel Combined With S-1 for HER2-Negative Metastatic Breast Cancer.
Morimoto M; Toba H; Aoyama M; Nakagawa M; Takechi H; Yoshida T; Tangoku A
Clin Breast Cancer; 2020 Dec; 20(6):448-453. PubMed ID: 32800494
[TBL] [Abstract][Full Text] [Related]
31. Switch maintenance therapy with S-1 after induction therapy with carboplatin and nanoparticle albumin-bound paclitaxel in advanced lung squamous cell carcinoma.
Akiyama N; Karayama M; Inui N; Yasui H; Hozumi H; Suzuki Y; Furuhashi K; Fujisawa T; Enomoto N; Nakamura Y; Inami N; Matsuura S; Kaida Y; Uto T; Matsui T; Asada K; Matsuda H; Fujii M; Toyoshima M; Suda T
Invest New Drugs; 2019 Jun; 37(3):531-537. PubMed ID: 30790149
[TBL] [Abstract][Full Text] [Related]
32. [Combination chemotherapy with S-1 and cisplatin for non-small cell lung cancer].
Wataya H; Ichinose Y
Gan To Kagaku Ryoho; 2006 Jun; 33 Suppl 1():194-6. PubMed ID: 16898001
[TBL] [Abstract][Full Text] [Related]
33. Oxaliplatin plus S-1 with intraperitoneal paclitaxel for the treatment of Chinese advanced gastric cancer with peritoneal metastases.
Shi M; Yang Z; Lu S; Liu W; Ni Z; Yao X; Hua Z; Feng R; Zheng Y; Wang Z; Sah BK; Chen M; Zhu Z; He C; Li C; Zhang J; Yan C; Yan M; Zhu Z
BMC Cancer; 2021 Dec; 21(1):1344. PubMed ID: 34922478
[TBL] [Abstract][Full Text] [Related]
34. A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer.
Yamamoto N; Hayashi H; Planchard D; Morán T; Gregorc V; Dowell J; Sakai H; Yoh K; Nishio M; Cortot AB; Benhadji KA; Soni N; Huang J; Makris L; Cedres S
Invest New Drugs; 2020 Oct; 38(5):1588-1597. PubMed ID: 32246224
[TBL] [Abstract][Full Text] [Related]
35. A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.
Chiappori AA; Ellis PM; Hamm JT; Bitran JD; Eiseman I; Lovalvo J; Burnett D; Olson S; Lenehan P; Zinner RG
J Thorac Oncol; 2006 Nov; 1(9):1010-9. PubMed ID: 17409987
[TBL] [Abstract][Full Text] [Related]
36. A phase I study of S-1 with concurrent thoracic radiotherapy in elderly patients with localized advanced non-small cell lung cancer.
Takigawa N; Kiura K; Hotta K; Hosokawa S; Nogami N; Aoe K; Gemba K; Fujiwara K; Harita S; Takemoto M; Himei K; Shinkai T; Fujiwara Y; Takata S; Tabata M; Kanazawa S; Tanimoto M;
Lung Cancer; 2011 Jan; 71(1):60-4. PubMed ID: 20451285
[TBL] [Abstract][Full Text] [Related]
37. Weekly paclitaxel plus bevacizumab versus docetaxel as second- or third-line treatment in advanced non-squamous non-small-cell lung cancer: Results of the IFCT-1103 ULTIMATE study.
Cortot AB; Audigier-Valette C; Molinier O; Le Moulec S; Barlesi F; Zalcman G; Dumont P; Pouessel D; Poulet C; Fontaine-Delaruelle C; Hiret S; Dixmier A; Renault PA; Becht C; Raffy O; Dayen C; Mazieres J; Pichon E; Langlais A; Morin F; Moro-Sibilot D; Besse B
Eur J Cancer; 2020 May; 131():27-36. PubMed ID: 32276179
[TBL] [Abstract][Full Text] [Related]
38. Phase II trial of carboplatin, S-1, and gefitinib as first-line triplet chemotherapy for advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations.
Tamiya A; Tamiya M; Shiroyama T; Saijo N; Nakatani T; Minomo S; Tsuji T; Takeuchi N; Omachi N; Kurata K; Suzuki H; Okamoto N; Okishio K; Hirashima T; Atagi S
Med Oncol; 2015 Mar; 32(3):40. PubMed ID: 25616723
[TBL] [Abstract][Full Text] [Related]
39. UFT plus vinorelbine in advanced non-small cell lung cancer: a phase I and an elderly patient-directed phase II study.
Igishi T; Shigeoka Y; Yasuda K; Suyama H; Katayama S; Sugitani A; Matsumoto S; Yamamoto M; Ueda Y; Takeda K; Sumikawa T; Sako T; Kodani M; Hitsuda Y; Shimizu E
J Thorac Oncol; 2009 Mar; 4(3):376-82. PubMed ID: 19190514
[TBL] [Abstract][Full Text] [Related]
40. Phase I/II study of docetaxel and S-1 in patients with previously treated non-small cell lung cancer.
Atagi S; Kawahara M; Kusunoki Y; Takada M; Kawaguchi T; Okishio K; Kubo A; Uehira K; Yumine K; Tomizawa Y; Saito R; Fukai S; Komatsu H
J Thorac Oncol; 2008 Sep; 3(9):1012-7. PubMed ID: 18758304
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
